Clinical Edge Journal Scan

Early PsA Diagnosis May Yield Better Outcomes


 

Key clinical point: A long delay (>1 year) in diagnosing psoriatic arthritis (PsA) is associated with worse clinical outcomes, especially in women and patients with enthesitis, chronic back pain, and lower C-reactive protein (CRP) levels.

Major finding: Patients with a short (<12 weeks) vs long delay (>1 year) in PsA diagnosis after symptom onset was more likely to achieve minimum disease activity (odds ratio 2.55; 95% CI 1.37-4.76). Female sex, chronic back pain (age < 45 years), enthesitis, and lower CRP levels were associated with a diagnostic delay > 1 year in patients with PsA (all P < .05).

Study details: This study included 708 newly diagnosed patients with PsA who were followed up for ≥3 years; were naive to disease-modifying antirheumatic drugs; and were categorized into groups having short (n = 136), intermediate (12 weeks to 1 year; n = 237), or long (n = 335) delay to diagnosis after symptom onset.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: The earlier the better? RMD Open. 2024;10:e004062 (Feb 27). doi: 10.1136/rmdopen-2023-004062 Source

Recommended Reading

FDA Approves 10th Humira Biosimilar, With Interchangeability
MDedge Rheumatology
Commentary: PsA Comorbidities and Treatment Safety and Effectiveness, March 2024
MDedge Rheumatology
Study Evaluates Factors Driving Fatigue in Patients With Psoriasis, PsA
MDedge Rheumatology
How Good are Tools to Screen for Spondyloarthritis in Patients With Psoriasis, Uveitis, IBD?
MDedge Rheumatology
Leflunomide: A Fresh Look at an Old Drug
MDedge Rheumatology
AI’s Future and Current Role in Rheumatology
MDedge Rheumatology
Ixekizumab Improves Distal Interphalangeal Joint Involvement and Adjacent Nail Psoriasis in PsA
MDedge Rheumatology
Similar Incidences of MACE in Patients with PsA and RA
MDedge Rheumatology
Bimekizumab Shows Long-term Benefits in PsA with Inadequate Response or Intolerance to TNFi
MDedge Rheumatology
Certain Gut Microbiota and Serum Metabolites May Protect Against PsA
MDedge Rheumatology